Mark Coleman Sells 5,537 Shares of Axsome Therapeutics (NASDAQ:AXSM) Stock

Axsome Therapeutics, Inc. (NASDAQ:AXSM) Director Mark Coleman sold 5,537 shares of the stock in a transaction dated Tuesday, June 2nd. The stock was sold at an average price of $223.39, for a total transaction of $1,236,910.43. Following the completion of the transaction, the director directly owned 29,603 shares of the company’s stock, valued at $6,613,014.17. This trade represents a 15.76% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website.

Mark Coleman also recently made the following trade(s):

• On Monday, June 1st, Mark Coleman sold 6,000 shares of Axsome Therapeutics stock. The stock was sold at an average price of $230.30, for a total transaction of $1,381,800.00.
• On Friday, May 29th, Mark Coleman sold 6,000 shares of Axsome Therapeutics stock. The stock was sold at an average price of $233.46, for a total transaction of $1,400,760.00.

Axsome Therapeutics Stock Up 5.0%

AXSM stock opened at $233.31 on Thursday. The stock has a market capitalization of $12.01 billion, a P/E ratio of -62.55 and a beta of 0.61. The company has a current ratio of 1.39, a quick ratio of 1.32 and a debt-to-equity ratio of 2.27. Axsome Therapeutics, Inc. has a 12 month low of $96.09 and a 12 month high of $238.56. The firm has a 50-day moving average price of $199.79 and a 200-day moving average price of $177.40.

Axsome Therapeutics (NASDAQ:AXSM) last posted its earnings results on Monday, May 4th. The company reported ($1.26) EPS for the quarter, missing analysts’ consensus estimates of ($0.85) by ($0.41). The company had revenue of $191.20 million during the quarter, compared to the consensus estimate of $191.10 million. Axsome Therapeutics had a negative return on equity of 267.16% and a negative net margin of 26.59%.Axsome Therapeutics’s quarterly revenue was up 57.4% compared to the same quarter last year. As a group, equities research analysts anticipate that Axsome Therapeutics, Inc. will post -2.14 EPS for the current fiscal year.

Institutional Trading of Axsome Therapeutics

Institutional investors have recently added to or reduced their stakes in the stock. Vanguard Group Inc. lifted its stake in Axsome Therapeutics by 6.0% in the third quarter. Vanguard Group Inc. now owns 4,180,646 shares of the company’s stock valued at $507,739,000 after buying an additional 235,626 shares during the period. Price T Rowe Associates Inc. MD lifted its stake in Axsome Therapeutics by 45.5% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 1,509,870 shares of the company’s stock valued at $275,763,000 after buying an additional 472,422 shares during the period. Wellington Management Group LLP lifted its stake in Axsome Therapeutics by 84.1% in the third quarter. Wellington Management Group LLP now owns 1,334,560 shares of the company’s stock valued at $162,082,000 after buying an additional 609,516 shares during the period. Invesco Ltd. lifted its stake in Axsome Therapeutics by 28.6% in the fourth quarter. Invesco Ltd. now owns 1,273,494 shares of the company’s stock valued at $232,591,000 after buying an additional 282,937 shares during the period. Finally, Geode Capital Management LLC lifted its stake in Axsome Therapeutics by 1.3% in the fourth quarter. Geode Capital Management LLC now owns 1,010,249 shares of the company’s stock valued at $184,544,000 after buying an additional 12,549 shares during the period. 81.49% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

Several research analysts have recently issued reports on AXSM shares. Deutsche Bank Aktiengesellschaft set a $280.00 price objective on Axsome Therapeutics in a research note on Tuesday, May 5th. Royal Bank Of Canada upped their price objective on Axsome Therapeutics from $242.00 to $302.00 and gave the company an “outperform” rating in a research note on Tuesday, May 5th. Piper Sandler reaffirmed an “overweight” rating and issued a $258.00 price objective on shares of Axsome Therapeutics in a research note on Monday, May 4th. Wells Fargo & Company upped their price objective on Axsome Therapeutics from $225.00 to $255.00 and gave the company an “overweight” rating in a research note on Tuesday, May 5th. Finally, Jefferies Financial Group upped their price objective on Axsome Therapeutics from $245.00 to $275.00 and gave the company a “buy” rating in a research note on Monday, May 4th. One investment analyst has rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $251.26.

About Axsome Therapeutics

Axsome Therapeutics, Inc is a clinical-stage biopharmaceutical company dedicated to developing novel therapies for central nervous system (CNS) disorders. The company focuses on small-molecule drugs designed to address unmet medical needs in areas such as depression, migraine, narcolepsy and fibromyalgia. Axsome employs a precision medicine approach, leveraging pharmacologic innovation to target underlying mechanisms of disease and improve patient outcomes.

Axsome’s pipeline includes several late-stage and approved product candidates.